Researchers devise a progression risk-based classification for patients with AWM
IMAGE: Mark Bustoros, MD view more Credit: Dana-Farber Cancer Institute By analyzing data from hundreds of patients with asymptomatic Waldenström macroglobulinemia (AWM), researchers at Dana-Farber Cancer Institute have devised a risk model for determining whether patients with AWM have a low, intermediate, or high risk of developing symptomatic Waldenström macroglobulinemia (WM), which requires chemotherapy treatment. Waldenström…
Details